Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma

Asthma is a heterogeneous chronic disease of airways. One of its endotypes is eosinophilic asthma, accompanied by both peripheral blood and airway eosinophilia, where severe eosinophilia is usually associated with more severe asthma. Anti - interleukin-5 (IL-5) monoclonal antibodies (MAb) can reduce...

ver descrição completa

Detalhes bibliográficos

Principais autores:	A S Kolbin, S N Avdeev, M V Zhuravleva, Yu M Gomon, Yu E Balykina, N V Matveyev, M A Proskurin, S V Fedosenko
Formato:	Artigo
Idioma:	Russo
Publicado em:	"Consilium Medicum" Publishing house 2019-12-01
coleção:	Терапевтический архив
Assuntos:	pharmacoeconomics reslizumab omalizumab severe eosinophilic asthma budget impact analysis cost effectiveness analysis monoclonal antibodies interleukin-5 direct costs
Acesso em linha:	https://ter-arkhiv.ru/0040-3660/article/viewFile/33739/pdf
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!